Objective-The objective of this study is to determine the role and underlying mechanisms of RGC-32 (response gene to complement 32 protein) in atherogenesis. Approach and Results-RGC-32 was mainly expressed in endothelial cells of atherosclerotic lesions in both ApoE -/-(apolipoprotein E deficient) mice and human patients. Rgc-32 deficiency (Rgc32 -/-) attenuated the high-fat diet-induced and spontaneously developed atherosclerotic lesions in ApoE -/-mice without affecting serum cholesterol concentration.
A therosclerosis is a major cause of coronary artery disease, stroke, and peripheral vascular diseases. Atherosclerotic lesion is characterized by the accumulation of lipid particles and immune cells in the subendothelial space, resulting in narrowing of the arterial lumen. Endothelial cell (EC) activation upon exposure to oxidized lipids and proinflammatory stimuli, such as TNF-α (tumor necrosis factor-α), plays an important role in the initiation and progression of atherosclerosis.
1,2 Activated ECs express adhesion molecules, such as ICAM-1 (intercellular adhesion molecule-1) and VCAM-1 (vascular cell adhesion molecule-1), and mediate the interaction between leukocytes and vascular ECs, which is critical for the atherogenesis. [3] [4] [5] [6] NF (nuclear factor)-κB is an important regulator of endothelial ICAM-1 and VCAM-1 expression. [7] [8] [9] [10] Both ICAM-1 and VCAM-1 promoters contain NF-κB-binding sites. 11, 12 Remarkably, EC-specific NF-κB inhibition abrogates adhesion molecule induction in ECs, impairs macrophage recruitment to atherosclerotic plaques, and protects mice from atherosclerosis, 13 indicating the critical role of endothelial NF-κB signaling in the pathogenesis of atherosclerosis. However, the factors that regulate NF-κB function in ICAM-1 and VCAM-1 transcription remain largely unknown.
RGC-32 (response gene to complement 32 protein) is expressed in numerous organs and tissues and is functionally involved in cell proliferation, 14, 15 differentiation, 16 and cancer. [17] [18] [19] It is induced by p53 in glioma and forms a protein complex with polo-like kinase 1 leading to G2/M arrest. 20 It also mediates transforming growth factor-β-induced epithelial-mesenchymal transition in human renal proximal tubular cells through interacting with Smad3 (SMAD family member 3). 21, 22 Recent studies from our laboratory show that RGC-32 expression is induced in mouse adipose and liver tissues with high-fat diet (HFD) challenge. Rgc-32 deficiency (Rgc32 -/-) protects mice from HFD-induced obesity and hepatic steatosis, 23, 24 suggesting that RGC-32 plays an important role in inflammatory and metabolic disease. A recent study indicates that RGC-32 is expressed in the human atherosclerotic arterial wall and mediates C5b-9-induced vascular EC proliferation and migration. 25 Whether or not RGC-32 plays a functional role in atherosclerosis and endothelial inflammation, however, remains to be determined.
In the present study, we found that RGC-32 is induced predominantly in ECs of atherosclerotic lesions and promotes the development of atherosclerosis. RGC-32 seems to mediate monocyte-EC interaction by stimulating the expression of endothelial ICAM-1 and VCAM-1, at least partially, via NF-κB signaling pathway.
Materials and Methods

Animals
The WT (wild type) C57BL/6 mice were purchased from the Jackson Laboratory (Bar Harbor, ME).
Rgc32
-/-mice on the C57BL/6 background were generated and genotyped as described previously. 26 
-/-mice were bred with C57BL/6 ApoE -/-(apolipoprotein E deficient) mice (Jackson Laboratories) to generate ApoE -/-Rgc32 -/-mice. Eight-week-old male ApoE -/-or ApoE -/-Rgc32 -/-mice were fed an HFD (D12108C; Research Diets, Inc) for 12 weeks or normal chow diet for 1 year for atherosclerotic lesion development. All animals we used in this study were male and housed under conventional conditions in the animal care facilities and received humane care in compliance with the Principles of Laboratory Animal Care formulated by the National Society for Medical Research and the Guide for the Care and Use of Laboratory Animals. All experimental procedures were approved by the Institutional Animal Care and Use Committee of the University of Georgia.
Human Atherosclerosis Specimen Collection
Human atherosclerotic plaque specimens were obtained from the patients undergoing off-pump coronary artery bypass grafting surgery at the Department of Cardiovascular Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University. The study was approved by Renji Hospital Ethics Committee and performed in accordance with the ethical standards.
Atherosclerotic Lesion Analysis and Metabolic Profiling
Mice were anesthetized using 2% isoflurane inhalation. Body weight was recorded, and blood was withdrawn by cardiac puncture. Serum was prepared and analyzed for triglyceride, cholesterol, and PCSK9 (proprotein convertase subtilisin/kexin type 9) concentration using Triglyceride Quantification Kit (ab65336; Abcam), high-density lipoprotein and low-density lipoprotein/very low-density lipoprotein cholesterol assay kit (ab65390; Abcam), and Human PCSK9 Picokine ELISA Kit (EK1147; Boster Biological Technology), respectively, following the manufacturer's instructions as described previously. 23 Mouse hearts with aortic roots, whole aortas, and livers were harvested. For en face plaque analyses, the aortas were opened longitudinally, fixed in 4% paraformaldehyde overnight, stained with Oil Red O for 1 hour, and rinsed with 70% ethanol. The hearts with the aortic roots were embedded in optimal cutting temperature compound, and 10-μm mouse aortic root sections were stained with Oil Red O as described. 27 Images were viewed and captured by a Nikon microscope. The atherosclerotic lesion areas were quantified using ImageJ. Oil Red O staining of the frozen liver sections (10 μm) and quantitative analysis was performed as described previously. 24, 27 Liver triglyceride content was determined using Triglyceride Quantification Kit (ab65336; Abcam) following the manufacturer's instructions.
Cell Culture
Mouse aortic ECs and smooth muscle cells (SMCs) were isolated and cultured as described previously. 28, 29 Briefly, mice were anesthetized using 2% isoflurane inhalation. The midline of the abdomen was incised, and the thorax opened to expose the heart and lungs. The abdominal aorta was cut at the middle to release the blood and then perfused with 1 mL of PBS containing 1000 U/mL of heparin from the left ventricle. The aorta was dissected out from the aortic arch to the abdominal aorta and immersed in DMEM containing 20% fetal bovine serum (FBS) and 1000 U/mL of heparin. The fat or connecting tissue was rapidly removed with fine forceps under a stereoscopic microscope. A 24-gage cannula was inserted into the proximal portion of the aorta. After ligation at the site with a silk thread, the inside of the lumen was briefly washed with serum-free DMEM. The other side was bound and filled with collagenase type II solution (1 mg/mL, dissolved in serum-free DMEM, LS004176; Worthington Biochemical Corporation). After incubation at 37°C for 45 minutes, adventitia was removed from the artery using 2 fine forceps under a dissecting microscope. ECs were removed from the aorta by flushing with 5 mL of DMEM containing 20% FBS. ECs were collected by centrifugation at 1200 rpm for 5 minutes, and the precipitate was gently resuspended by pipette with 2 mL of DMEM with 20% FBS and cultured in a 35-mm type I collagen-coated dish. After incubation at 37°C for 2 hours, the medium was removed, and the cells were washed with warm PBS. Then, medium G (20% FBS [S11550H; Atlanta Biologicals], 100 U/mL penicillin G, 100 μg/mL streptomycin [SV30010; Hyclone], 2 mmol/L L-glutamine [25- ; Sigma], 100 μg/mL heparin, 100 μg/mL endothelial cell growth supplement [E2759; Sigma], and DMEM) was added. For SMC isolation, the artery was incubated in DMEM with 10% FBS overnight, followed by incubation with 1 mg/mL collagenase type II and 0.5 mg/mL elastase (E-0258; Sigma) at 37°C for 30 minutes. The artery was gently triturated with a 1 mL pipette, and then 10 mL of the culture medium was added to terminate the digestion. Cells were collected by centrifugation at 1800 rpm for 10 minutes, and the precipitate was gently resuspended in DMEM containing 10% FBS and cultured under 37°C in a 5% CO 2 condition.
Human umbilical vein ECs (HUVECs) were purchased from Lifeline Cell Technology (FC-0003) and cultured using VEGF (vascular endothelial growth factor) endothelial medium (LL-0003) under 37°C, 5% CO 2 conditions. The cells at passages 3 to 5 were used in this study.
The cultured cells were treated with vehicle or 20 ng/mL of TNF-α (GF023; Sigma) for indicated times without starvation. quantitative PCR with All-in-One qPCR Mix (QP001; GeneCopoeia) using the Mx3005P qPCR machine as described previously. 26 Each sample was amplified in triplicate. The expression of each gene was normalized with cyclophilin. The primers used are listed in Table I in the online-only Data Supplement.
Quantitative Real-Time Polymerase Chain Reaction
Western Blot Analysis
Primary cultured ECs, SMCs, or HUVECs were washed twice with PBS followed by protein extraction using radioimmunoprecipitation assay buffer (50 mmol/L Tris-HCL, pH 7.4, 1% Triton X-100, 0.25% wt/vol sodium deoxycholate, 150 mmol/L NaCl, 1 mmol/L EGTA, and 0.1% SDS) containing protease inhibitors (78428; Thermo Scientific). The protein concentration was measured using BCA Protein Assay Reagent (23225; Thermo Scientific). Lysates were denatured by boiling in gel loading buffer containing SDS and 2-mercaptoethanol solution. Cell lysates were resolved on a 9% or 12% SDS-PAGE and then transferred to polyvinylidene difluoride membranes (1620177; Bio-Rad). Membranes were blocked with 5% skimmed milk and then incubated with primary antibodies at 4°C overnight followed by incubation with HRP-conjugated secondary antibody (Sigma) at room temperature for 1 hour. Protein expression was detected with an enhanced chemiluminescence (WBKLS0500; Millipore). Antibodies against RGC-32 (1:1000), ICAM-1 (1:1000, ab124760; Abcam), VCAM-1 (1:1000, ab134047; Abcam), P-selectin (1:1000, ab178424; Abcam), phospho-NF-κB p65 (1:1000, 13346S; Cell Signaling Tech), NF-κB p65 (1:1000, 8242S; Cell Signaling Tech), and α-tubulin (1:1000, T6074; Sigma) were used for immunoblotting.
Histochemistry and Immunohistology Analysis
After fixing in 4% paraformaldehyde overnight, the hearts with aortic roots were dehydrated in a graded series of ethanol and xylene solutions, embedded in paraffin, and sectioned (5 μm). The sections were deparaffinized in xylene and rehydrated. Collagen content in the lesion was measured using a Masson Trichrome Staining Kit (KTMTR2; American MasterTech) by following the manufacturer's instruction. To measure fibrous cap thickness, at least 3 measurements of the thinnest fibrous cap within 1 atherosclerotic plaque were taken and averaged as described previously. 30 For immunohistochemistry staining, the sections underwent microwave antigen retrieval in 10 mmol/L citrate buffer (pH 6.0), were allowed to cool down to room temperature, and were washed with PBS. The endogenous peroxidase activity was quenched by the addition of 3% H 2 O 2 . Subsequently, slides were washed with PBS, and nonspecific antibody binding was blocked by incubation with 10% goat serum for 30 minutes at room temperature. The sections were then incubated with RGC-32 (1:200), α-SMA (α-smooth muscle actin; 1:200, A5228; Sigma), CD68 (1:200, MCA1957; Bio-Rad), ICAM-1 (1:200, ab124760; Abcam), VCAM-1 (1:200, ab134047; Abcam) primary antibody, or corresponding normal IgG (negative control) at 4°C overnight followed by incubation with horseradish peroxidase-conjugated secondary antibody. The sections were counterstained with hematoxylin. Images were captured with a charge-coupled device camera mounted on a Nikon microscope. Quantification was performed using ImageJ Immunohistochemistry Image Analysis Toolbox. For immunofluorescent staining, the hydrated sections underwent microwave antigen retrieval as described above, washed with PBS, and blocked with 10% goat serum for 30 minutes at room temperature, followed by incubation with RGC-32 (1:100), CD31 (1:100, sc-365804; Santa Cruz Biotechnology), α-SMA (1:100; Sigma), CD68 (1:100, MCA1957; Bio-Rad), Ki67 (1:100, ab16667; Abcam) primary antibody, or corresponding normal IgG (negative control) at 4°C overnight. Then, the sections were incubated with FITC (fluorescein isothiocyanate)-(1:100) or TRITC (tetramethylrhodamine-isothiocyanate)-labeled (1:50) secondary antibody at room temperature for 1 hour. Nuclei were stained with DAPI (4′,6-diamidino-2-phenylindole, H-1500; Vector Laboratories). Fluorescent images were captured using a Nikon fluorescent microscope.
Cell immunofluorescence was performed as described previously. 26 HUVECs were cultured on glass coverslips and treated as indicated. Then the cells were fixed with 4% paraformaldehyde, permeabilized with 0.2% Triton X-100 in PBS, and incubated with 10% normal goat serum for 30 minutes at room temperature. The cells were incubated overnight at 4°C with anti-NF-κB p65 (1:100) or anti-RGC-32 (1:100) primary antibody and then TRITC-labeled (1:50) secondary antibody for 1 hour at room temperature. Nuclei were stained with DAPI. Fluorescence images were captured by a Nikon fluorescent microscope. Quantification analysis was performed using ImageJ.
Bone Marrow Transplantation
Eight-week-old male WT and Rgc32 -/-recipient mice were lethally irradiated with 1100 rad 4 hours before transplantation. Bone marrow (BM) was collected from the femurs and tibias of the age-matched WT male donor mice by flushing with sterile PBS. Each recipient mouse was injected with 5×10 6 BM cells (200 μl in PBS) through the tail vein. These recipient mice were maintained under sterile specificpathogen-free conditions and with antibiotic treatment (sulfatrim at 1.6 mg/mL in drinking water) for 4 weeks to allow recovery from the irradiation. Then, these mice received a single injection of recombinant adeno-associated virus ( 1×10 11 ) expressing human D374Y-PCSK9 (rAAV8-D374Y-hPCSK9) followed by an HFD challenge for 12 weeks to induce atherosclerosis. 
Monocyte-EC Adhesion Assay
THP-1 cells (TIB-202; ATCC) were labeled with 2.5 µmol/L calcein acetoxymethyl (AM) (C1359; Sigma), or CM-DiI (V22888; ThermoFisher Scientific) in a 37°C 5% CO 2 incubator for 30 minutes. The labeled cells were washed with 10 mL of PBS for 3× to remove the residual calcein AM or CM-DiI. After the final wash, the cells were gently resuspended at a final concentration of 1×10 6 cells/mL in culture medium. Calcein AM-labeled THP-1 cells (1×10 6 ) were added to a confluent monolayer of primary cultured ECs, which were treated with vehicle or 20 ng/mL of TNF-α (GF023; Sigma) for 24 hours. CM-DiI-labeled THP-1 cells (1×10 6 ) were added to a confluent monolayer of HUVECs, which were transduced with an adenovirus expressing GFP (Ad-GFP [green fluorescent protein]), RGC-32 shRNA (Ad-shRGC32), or RGC-32 cDNA (Ad-RGC32). Ad-RGC32 was constructed previously. 32 The target sequence of shRGC32 is 5′-GAT TCA CTT TAT AGG AAC AGC TT-3′. Ad-shRGC32 was generated as described previously. 32 After incubation in a 37°C 5% CO 2 incubator for 1 hour, the cells were gently washed with PBS for 3×, and the number of adherent calcein AM-(green fluorescent signal), or CM-DiI-labeled (red fluorescent signal) THP-1 cells were determined under a Nikon fluorescence microscope. Measurements were performed for at least 10 different view fields.
Luciferase Activity
The human ICAM-1 promoter DNA fragments from −500 to +45 bp and VCAM-1 promoter DNA fragments from −504 to +45 bp relative to the mapped transcription start sites were obtained by PCR amplification from human genomic DNA using primers containing restriction enzyme sites for KpnI or XhoI. The primers used are listed in Table II in the online-only Data Supplement. The PCR fragments were digested with restriction enzymes and cloned into the pGL4 vector. Transient transfection and luciferase assay were performed as described previously. 24 Briefly, HUVECs were transduced with Ad-GFP, Ad-shRGC32, or Ad-RGC32. Twenty-four hours later, ICAM-1 or VCAM-1 promoter construct was transfected into the cells with Lipofectamine LTX (15338100; Invitrogen) for 48 hours followed by the treatment with vehicle or 20 ng/mL of TNF-α for 48 hours. Luciferase activities were measured using the Dual-Luciferase Reporter Assay System (E1960; Promega). For each sample, a Renilla luciferase vector was cotransfected as an internal control, and promoter activities were normalized accordingly.
Coimmunoprecipitation Assay
Coimmunoprecipitation assay was performed as described previously. 33 In brief, HUVECs were transduced with Ad-GFP, Ad-shRGC32, or Ad-RGC32 for 48 hours, followed by vehicle or 20 ng/mL of TNF-α treatment for 6 hours. Cells were then lysed with ice-cold lysis buffer containing protease inhibitor mix (78430; Thermo Scientific). The lysates were incubated with immunoglobulin G (IgG, sc-2027; Santa Cruz Biotechnology), RGC-32, or NF-κB p65 (Cell Signaling Technology) antibodies at 4°C overnight by following the instruction provided in the CoIP kit (26149; Thermo Scientific). The immunoprecipitates were pelleted, washed, and subjected to immunoblotting using RGC-32 or NF-κB p65 antibody.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation assays were performed using a ChIP assay kit (17-295; Millipore) as described previously. 24 Briefly, HUVECs were transduced with Ad-GFP, Ad-shRGC32, or Ad-RGC32 for 48 hours, followed by vehicle or TNF-α (20 ng/mL) treatment for 6 hours. Cross-linking with 1% formaldehyde was performed at 37°C for 10 minutes. The cells were washed twice by PBS and lysed in the lysis buffer at 4°C for 1 hour and sonicated. The sonicated cells were centrifuged at 13 000 g for 10 minutes at 4°C, and the supernatants were diluted using the dilution buffer. After protein measurement, equal amount of proteins was used as input control or for immunoprecipitation with NF-κB p65, RGC-32 antibody, or normal rabbit IgG at 4°C overnight. Protein A-agarose beads were added and incubated at 4°C for 1 hour. Then, the beads were washed, and samples were eluted with elution buffer. The samples were incubated at 65°C for 4 hours to reverse the cross-linking, and the DNA was extracted with phenol/chloroform and used for semiquantitative and quantitative PCR. Primers for amplifying the ICAM-1 promoter were designed between −146 and −265 bp spanning the NF-κB element. For the VCAM-1 promoter, primers were designed to amplify the region between −160 and the transcription start site spanning the NF-κB element. Primers used in chromatin immunoprecipitation assays are listed in Table III in the online-only Data Supplement.
Data Analysis
All values are expressed as the mean±SEM. For statistical analysis, 2 groups were compared using 2-tailed Student t tests ( Figures 2B,  2D , 2F, 2H, 3B, 3D, 4B, 4D, 4F, 5B, and 5D; Figures II, III, IV, VI, and VII in the online-only Data Supplement), and 3 groups were evaluated by 1-way analysis of variance followed by Tukey multiple comparisons ( Figures 1B, 1D , and 5K; Figure V in the online-only Data Supplement). Four groups were evaluated by 2-way analysis of variance followed by Bonferroni post hoc tests for multiple comparisons ( Figures 5E, 5G , 5I, and 6B through 6H) using GraphPad Prism 5.0 software. Data were considered statistically significant if P value was <0.05.
Results
RGC-32 Was Mainly Expressed in ECs of Atherosclerotic Lesions
To detect RGC-32 expression in human normal vessel and atherosclerotic lesions, we performed immunohistochemistry staining with RGC-32 antibody or normal rabbit IgG (negative control). RGC-32 was undetectable in human normal vessel, but it was significantly induced in the early stage and highly upregulated in advanced stage of atherosclerotic lesions ( Figure 1A and 1B) . Immunostaining of the aortic roots of WT and ApoE -/-mice fed with normal chow or HFD for 12 weeks with RGC-32 antibody or normal rabbit IgG (negative control) showed results similar to the human vessels. Although no detectable RGC-32 was observed in the aortic roots from WT and ApoE -/-mice fed with normal chow that had no atherosclerotic lesions, it was induced in aortic roots from ApoE -/-mice fed with HFD ( Figure 1C and 1D) . Interestingly, RGC-32 expression was predominantly located in the inner layer of the vessel with the atherosclerotic lesions, suggesting that RGC-32 was expressed in ECs. To confirm this, we performed a coimmunostaining of RGC-32 with EC marker CD31, SMC marker α-SMA, or corresponding normal IgG (negative controls). As shown in Figure 1E , RGC-32 was colocalized with CD31, but not α-SMA ( Figure I in the onlineonly Data Supplement), indicating that RGC-32 was primarily expressed in ECs of the atherosclerotic lesions, which may be important for the development of atherosclerosis.
RGC-32 Deficiency Attenuated Atherosclerotic Lesion Development
To determine whether RGC-32 plays a role in the development of atherosclerosis, we generated ApoE
Rgc32
-/-double knockout mice. These mice were fed HFD for 12 weeks or chow diet for 1 year. Oil Red O staining was performed to detect the atherosclerotic lesion formation in aortas and aortic roots. As shown in Figure 2A through 2D, the area of atherosclerotic lesions seen in ApoE
-/-mice was significantly smaller than that in ApoE -/-mice. Rgc32 -/-also reduced the size of the spontaneously developed atherosclerotic lesion in the 1-year-old ApoE -/-mice fed with chow diet ( Figure 2E through 2H) . Because blood lipoproteins, in particular low-density lipoprotein and high-density lipoprotein, are critical for the development of atherosclerosis, 34, 35 we tested whether Rgc32 -/-inhibited atherosclerosis through changing the lipoprotein levels. Thus, serum isolated from ApoE -/-and ApoE
-/-mice was subjected to lipoprotein profiling. However, no significant difference in any fraction of serum lipoproteins, triglyceride, or body weight was observed between these 2 groups (Figure IIA through IIC in the onlineonly Data Supplement). Liver steatosis is also highly associated with atherosclerosis. 36 However, Oil Red O staining of liver tissues and liver triglyceride assay showed that there was no difference of lipid deposition in the liver between ApoE 
RGC-32 Deficiency Attenuated Macrophage Infiltration in Atherosclerotic Lesions
The progression of atherosclerosis involves macrophage infiltration and accumulation in the intimal plaque region. 4 Disruption of the SMC layer in the media has been observed in large mouse aortic root lesions, along with the appearance of SMCs forming the fibrous cap. 37 Therefore, to gain further insight into the differences in atherosclerosis between ApoE -/-and ApoE
Rgc32
-/-mice, we analyzed the cellular composition of the atherosclerotic lesions. Interestingly, no significant difference in the collagen and SMC content in the lesion was observed between ApoE -/-and ApoE
-/-mice ( Figure 3A and 3B) . Thickness of the fibrous cap seemed not to be affected by Rgc32 -/-as well ( Figure 3A and 3B) . However, the macrophage content in the lesion significantly decreased in ApoE -/-
-/-mice relative to ApoE -/-mice ( Figure 3A  and 3B) . Monocyte adhesion and infiltration in the early stage and proliferation of local macrophages in the established lesions contribute to lesional macrophage accumulation. 38 Coimmunofluorescent staining of macrophage marker CD68 and proliferation marker Ki67 showed that Rgc32 -/-had no effect on the lesional macrophage proliferation ( Figure 3C and 3D), suggesting that the decreased macrophage content may be because of a suppression of monocyte adhesion and infiltration.
Resident Vascular Cell RGC-32 Was Essential for Atherosclerosis Development
Because ECs are the primary cells that express RGC-32 in atherosclerotic lesions (Figure 1 ), we sought to determine whether RGC-32 in resident vascular cells, such as ECs, contributed to atherosclerosis development. Thus, we transplanted BM cells of WT mice to the WT or Rgc32 -/-recipient mice. These mice then received a single injection of AAV (adeno-associated virus)-PCSK9 followed by an HFD challenge for 12 weeks to induce atherosclerosis. 31 PCSK9 is an enzyme that can bind to the receptor for low-density lipoprotein, induce its degradation, and will eventually lead to hypercholesterolemia. We used AAV-PCSK9 injection instead of ApoE -/-mice to prevent the effects of hypercholesterolemia on vascular inflammation and lesion development before BM transplantation. ApoE -/-mice develop atherosclerosis spontaneously because of hypercholesterolemia, and this may obscure the potential role of macrophage RGC-32 in the early stage of atherosclerosis before BM transplantation. En face analysis and aortic root Oil Red O staining of aorta and aortic roots showed that reconstitution of macrophage RGC-32 did not alter the function of Rgc32 −/− in reducing the lesion area. As a result, significant reduced lesion area was detected in Rgc32 -/-recipients compared with the WT recipients ( Figure 4A through 4D) . Macrophage accumulation in Rgc32 -/-recipients was also decreased compared with WT controls ( Figure 4E 
RGC-32 Deficiency Inhibited Endothelial ICAM-1 and VCAM-1 Expression Both In Vivo and In Vitro
Monocyte adhesion to ECs is one of the earliest cellular events in atherosclerosis development. The oxidized lipids or proinflammatory stimuli, such as TNF-α, activate ECs, which express ICAM-1, VCAM-1, or P-selectin attracting monocyte migration into the subendothelial space. Monocytes then differentiate into macrophages and phagocytize lipids, eventually becoming lipid-laden foam cells. [3] [4] [5] [6] To explore the mechanism by which Rgc32 -/-attenuated the macrophage infiltration and atherosclerosis development, we cultured the primary mouse aortic ECs from WT and Rgc32 -/-mice and detected the expression of adhesion molecules. Interestingly,
Rgc32
-/-inhibited the expression of endothelial ICAM-1 and VCAM-1 but not P-selectin ( Figure 5A and 5B). To confirm the effect of Rgc32 -/-on endothelial ICAM-1 and VCAM-1 expression in vivo, we immunostained the atherosclerotic lesion with ICAM-1, VCAM-1 antibody, or normal rabbit IgG (negative control). As shown in Figure 5C and 5D, endothelial ICAM-1 and VCAM-1 was significantly decreased in ApoE -/-Rgc32 -/-mice compared with ApoE -/-mice. In addition to ECs, vascular SMCs also express the cellular adhesion molecules ICAM-1 and VCAM-1 in atherosclerosis. 39 However, Rgc32 -/-seemed not to affect the expression of ICAM-1, VCAM-1, or P-selectin in cultured primary mouse aortic SMCs ( Figure IV in the online-only Data Supplement). These data suggest that RGC-32 mainly regulates endothelial ICAM-1 and VCAM-1 expression, which may mediate the adhesion of monocytes to ECs.
RGC-32 Deficiency Inhibited TNF-α-Induced Endothelial ICAM-1 and VCAM-1 Expression and Monocyte-EC Interaction
TNF-α plays an essential role in adhesion molecule expression and further atherosclerosis. 40 We, therefore, determined whether RGC-32 mediates TNF-α-induced endothelial ICAM-1 and VCAM-1 expression. The HUVECs were transduced with Ad-GFP, RGC-32 shRNA (Ad-shRGC32), or RGC-32 (Ad-RGC32) and then transfected with ICAM-1 or VCAM-1 promoter constructs. Luciferase activity assay was performed after vehicle or TNF-α treatment. Consistent with previous studies, TNF-α increased ICAM-1 and VCAM-1 promoter activities. 10 However, knockdown of RGC-32 diminished the TNF-α-increased promoter activities, whereas RGC-32 overexpression enhanced the promoter activities ( Figure 5E ), suggesting that RGC-32 played a critical role in TNF-α-induced endothelial ICAM-1 and VCAM-1 transcription. We also confirmed the regulation of ICAM-1 and VCAM-1 by RGC-32 at protein level in primary cultured mouse aortic ECs. TNF-α significantly induced both the ICAM-1 and VCAM-1 expression in WT ECs. However, Rgc32 -/-diminished the effect of TNF-α ( Figure 5F and 5G). To assess the functional significance of RGC-32 on ICAM-1 and VCAM-1 expression, we tested whether RGC-32 affects the monocyte-EC interaction. To this end, primary mouse aortic ECs were treated with vehicle or TNF-α for 24 hours and then incubated with calcein AM-labeled THP-1 cells. As shown in Figure 5H and 5I, TNF-α treatment increased the adhesion of THP-1 monocytes to WT ECs. Rgc32 -/-attenuated THP-1 adhesion with and without TNF-α treatment. To test the direct effect of RGC-32 on monocyte-EC interaction, RGC-32 was knocked down or overexpressed in HUVECs ( Figure V in the online-only Data Supplement) followed by incubation with CM-DiI-labeled THP-1 cells. As shown in Figure 5J and 5K, knockdown of RGC-32 suppressed, whereas overexpression of RGC-32 enhanced the adhesion of THP-1 monocytes to HUVECs. These results indicated that RGC-32 mediates TNF-α-induced endothelial ICAM-1 and VCAM-1 expression, which further facilitates the monocyte-EC interaction.
RGC-32 Mediated Endothelial ICAM-1 and VCAM-1 Expression, At Least Partially, Through NF-κB Signaling
Because NF-κB is a critical transcription factor regulating endothelial ICAM-1 and VCAM-1 expression, 41, 42 we hypothesized that RGC-32 may regulate endothelial ICAM-1 and VCAM-1 expression via NF-κB signaling. To test this hypothesis, we used ammonium pyrrolidinedithiocarbamate to block NF-κB signaling in HUVECs with forced expression of RGC-32. As shown in Figure 6A and 6B, RGC-32 overexpression induced ICAM-1 and VCAM-1 expression accompanied by an increased NF-κB phosphorylation (activation). Ammonium pyrrolidinedithiocarbamate blocked RGC-32-induced NF-κB phosphorylation, as well as ICAM-1 and VCAM-1 expression ( Figure 6A and 6B) . Consistently, knockdown of RGC-32 blocked, whereas overexpression of RGC-32 increased TNF-α-induced NF-κB nuclear translocation ( Figure VIA through VID in the online-only Data Supplement). These results indicated that RGC-32 regulates endothelial ICAM-1 and VCAM-1 expression, at least partially, through NF-κB signaling pathway.
To determine how RGC-32 regulates NF-κB function, we detected whether RGC-32 interacts with NF-κB. Coimmunoprecipitation assay showed that RGC-32 physically interacted with NF-κB, and TNF-α treatment significantly increased this interaction ( Figure 6C and 6D) . Because NF-κB regulates ICAM-1 and VCAM-1 transcription by binding to their promoters, we further determined whether RGC-32 affects the interaction of NF-κB with ICAM-1 and VCAM-1 promoters using a chromatin immunoprecipitation assay. As shown in Figure 6E and 6F, RGC-32 knockdown decreased, whereas RGC-32 overexpression increased TNF-α-induced NF-κB binding to the ICAM-1 and VCAM-1 promoters. Intriguingly, TNF-α induced RGC-32 nuclear translocation ( Figure VII in the online-only Data Supplement), and chromatin immunoprecipitation assay using RGC-32 antibody showed that TNF-α increased RGC-32 binding to the ICAM-1 and VCAM-1 promoters ( Figure 6G and 6H) . Our results demonstrated that RGC-32 directly binds with NF-κB and facilitates its binding to ICAM-1 and VCAM-1 promoters and thus promotes their expression during atherogenesis.
Discussion
Although atherosclerosis was once considered as a lipid storage disease, it is now recognized as a subacute inflammatory -/-(n=8) recipient mice were transplanted with bone marrow from WT mice. These mice then received a single injection of AAV-PCSK9 (adeno-associated virus-proprotein convertase subtilisin/kexin type 9) and were fed high-fat diet (HFD) for 12 wk. A, Representative images of en face Oil Red O staining of the aortas (scale bar=0.5 cm). B, Quantification of the atherosclerotic lesions in en face aortas shown in (A), which was expressed as percentage of lesions relative to total aortic area. C, Representative Oil Red O staining of aortic root (scale bar=500 μm). D, Quantification of aortic root lesion by measuring the Oil Red O-positive area. **P<0.01 compared with WT groups (n=8). E, Representative images of immunohistochemistry staining for macrophage accumulation (CD68) in aortic roots (scale bar=200 μm). F, Quantitative analysis of CD68-positive area shown in (E). **P<0.01 compared with WT groups (n=8).
condition of the vessel wall, characterized by infiltration of macrophages and T cells, which interact with one another and with cells in the arterial wall. 43 Recent study demonstrates that RGC-32 is expressed in human atherosclerotic arterial wall. 25 However, it is unclear whether RGC-32 plays a role in arterial inflammation and atherosclerosis development. Our current study demonstrates that RGC-32 is expressed strongly in ECs of both mouse and human atherosclerotic lesions (Figure 1) .
Rgc32
-/-mice exhibit significantly decreased atherosclerotic lesion development compared with ApoE -/-control mice under both HFD and chow diet conditions (Figure 2) , suggesting a critical role of RGC-32 in atherosclerosis.
The initial steps of atherosclerosis include adhesion of circulating monocytes to the ECs and migration of the adherent monocytes into the intima. 37 EC activation on exposure to oxidized lipids and proinflammatory stimuli, such as TNF-α, induces ICAM-1 and VCAM-1 expression, mediating adhesion of monocytes to ECs. [3] [4] [5] [6] Rgc32 -/-significantly reduces the macrophage content in atherosclerotic lesions ( Figure 3A and 3B) and decreases ICAM-1 and VCAM-1 expression in ECs (Figure 5A through 5D) . Rgc32 -/-also blocks TNF-α-induced endothelial ICAM-1 and VCAM-1 expression and monocyte-EC interaction ( Figure 5E through 5I) . In addition to ECs, vascular SMCs also express ICAM-1 and VCAM-1 in atherosclerosis. 39 Our in vivo data showed that ICAM-1 and VCAM-1 expression inside the lesion was decreased in ApoE
-/-mice compared with the ApoE -/-control mice ( Figure 5C ). However, Rgc32 
-/-(n=9) mice fed high-fat diet (HFD) for 12 wk. Staining with corresponding normal IgG served as negative controls. **P<0.01 compared with ApoE -/-groups (n=8-9; scale bar=100 μm). E, Human umbilical vein endothelial cells (HUVECs) were transduced with adenovirus expressing GFP (Ad-GFP [green fluorescent protein]), Ad-shRGC32, or Ad-RGC32 for 24 h, followed by transfection of ICAM-1 or VCAM-1 promoter construct and treatment with vehicle or 20 ng/mL TNF-α for 48 h. Luciferase assay was then performed, and luciferase activity was normalized to Renilla activity. **P<0.01 compared with Ad-GFP groups; ##P<0.01 compared with Ad-GFP groups treated with TNF-α (n=3). F and G, Primary mouse aortic ECs from WT and Rgc32 -/-mice were treated with vehicle or 20 ng/mL of TNF-α for 24 h. ICAM-1, VCAM-1, and RGC-32 protein expression was detected by Western blot and normalized to α-tubulin level. *P<0.05, **P<0.01 compared with WT groups treated with vehicle (−); ##P<0.01 compared with WT groups treated with TNF-α (n=6). H and I, WT and Rgc32 -/-primary mouse aortic EC monolayer was treated with vehicle or TNF-α for 24 h followed by incubation with calcein acetoxymethyl-labeled (green) THP-1 cells. After washing by PBS, the number of the adherent THP-1 cells in 10 random fields was counted. *P<0.05, **P<0.01 compared with WT groups treated with vehicle (−); ##P<0.01 compared with WT groups treated with TNF-α (n=3). J and K, HUVECs were transduced with Ad-GFP, Ad-shRGC32, or Ad-RGC32 for 48 h followed by incubation with CM-DiI-labeled (red) THP-1 cells. After washing by PBS, the number of the adherent THP-1 cells in 10 random fields was counted. *P<0.05, **P<0.01 compared with Ad-GFP groups (n=3; scale bar=100 μm).
there is a correlation between the extent of adhesion molecule expression in lesion SMC and macrophage infiltration. 39 TNF-α and IL (interleukin)-1β secreted by macrophages increase ICAM-1 and VCAM-1 expression in vascular SMCs. 44, 45 Moreover, the atherosclerotic lesion progression also involves the migration of SMCs from the media to the intima, proliferation of the SMCs, and increased synthesis of extracellular matrix, such as collagen. 43 However, RGC-32 seems not to alter the collagen or SMC content in atherosclerotic lesions ( Figure 3A and 3B) , suggesting that RGC-32 plays a minimal role in SMC function during atherosclerosis development.
Transcription factor NF-κB is a predominant regulator of endothelial ICAM-1 and VCAM-1 expression. [7] [8] [9] [10] Blockade of NF-κB abolishes adhesion molecule induction in ECs, which impairs monocyte recruitment to atherosclerotic plaques. 13 However, it is largely unknown how NF-κB regulates endothelial ICAM-1 and VCAM-1 expression. The present study demonstrates that RGC-32 directly interacts Western blot and normalized to α-tubulin level. Phosphorylation of NF-κB p65 was normalized to the total NF-κB p65 level. *P<0.05, **P<0.01 compared with Ad-GFP groups; ##P<0.01 compared with Ad-RGC32-alone groups. C-H, HUVECs were transduced with Ad-GFP, Ad-shRGC32, or Ad-RGC32 for 48 h and then treated with vehicle or 20 ng/mL TNF-α (tumor necrosis factor-α) for 6 h. C and D, Coimmunoprecipitation was performed with IgG, RGC-32, or NF-κB p65 antibody as indicated. The immunoprecipitates were immunoblotted (IB) with NF-κB p65 and RGC-32 antibody. E-H, Chromatin immunoprecipitation assay was performed to detect the NF-κB and RGC-32-binding enrichment to ICAM-1 (E and G) or VCAM-1 (F and H) promoter, as measured by semi-quantitative polymerase chain reaction (PCR) and real-time quantitative PCR. *P<0.05, **P<0.01 compared with Ad-GFP groups; #P<0.05, ##P<0.01 compared with Ad-GFP groups treated with TNF-α. All results are representative of at least 3 independent experiments.
